A Quiet Approval That Changes the Mitochondrial Peptide Story
On September 19, 2025, the FDA granted accelerated approval to a peptide drug called FORZINITY (elamipretide HCl, Stealth BioTherapeutics) for an ultra-rare genetic disease called Barth syndrome. Fewer than 300 people in the United States have it. The press cycle was, predictably, small.
But for anyone watching the mitochondrial peptide space, this was the approval the field had been waiting on for more than a decade.
Elamipretide isn't new. Most peptide researchers know it by its older name: SS-31 (Szeto-Schiller peptide #31). It's been in clinical development since the 2010s under multiple names — Bendavia, MTP-131 — across cardiology, ophthalmology, and rare mitochondrial disease. It's the most-studied mitochondria-targeted peptide in human medicine, and for many years the question wasn't whether it worked at the cellular level but whether any of those mechanisms would translate into the kind of clinical endpoint the FDA accepts as proof.
In 2025 it finally did. And the broader implications — for heart failure, for dry age-related macular degeneration, for the still-speculative idea that mitochondrial peptides might be a meaningful tool against aging itself — are larger than the narrow Barth syndrome label suggests.
Here's what actually happened, what the data really shows, and what to watch next.
What the FDA Actually Approved
FORZINITY is approved for the improvement of muscle strength in adult and pediatric patients with Barth syndrome who weigh at least 30 kg (about 66 pounds).
That's a precise label, and the precision matters. A few key facts from the prescribing information and the FDA's integrated review:
- Drug class: Mitochondria-targeted aromatic-cationic tetrapeptide (D-Arg-2',6'-Dmt-Lys-Phe-NH₂)
- Approval pathway: Accelerated approval based on a surrogate endpoint (muscle strength)
- Dose: 40 mg subcutaneously once daily; 20 mg in severe renal impairment (eGFR < 30, not on dialysis)
- Most common adverse reaction: Injection site reactions
- Confirmatory trial requirement: Stealth must complete additional trials to confirm clinical benefit
- Sponsor: Stealth BioTherapeutics
It is, structurally and mechanistically, the first FDA-approved drug whose primary mode of action is targeting cardiolipin in the inner mitochondrial membrane — a small but significant entry in the regulatory record book.
What Is Barth Syndrome (and Why a Peptide Helps)?
Barth syndrome is an X-linked recessive disorder caused by mutations in the TAZ gene, which encodes a protein called tafazzin. Tafazzin is a phospholipid remodeling enzyme — specifically, it remodels cardiolipin, the signature lipid of the inner mitochondrial membrane.
Cardiolipin matters because it organizes the protein complexes of the electron transport chain, stabilizes mitochondrial cristae structure, and is required for normal ATP production. When tafazzin is broken, cardiolipin matures incorrectly, mitochondrial membranes destabilize, ATP production drops, and the tissues that need the most mitochondrial output — cardiac muscle, skeletal muscle, neutrophils — start failing.
Boys with Barth syndrome typically present in infancy with cardiomyopathy, skeletal muscle weakness, growth delays, and recurrent infections. Median life expectancy has historically been short, though improved supportive care has helped. There has been no disease-specific treatment until now.
This is exactly the kind of disease where a cardiolipin-targeting peptide makes sense. Elamipretide selectively binds cardiolipin and stabilizes inner-membrane structure even in cells where the lipid composition is abnormal — partially compensating for what tafazzin can't do.
How Elamipretide Works
Elamipretide is what's called an SS peptide (Szeto-Schiller peptide), a small family of compounds engineered by Hazel Szeto and Peter Schiller in the early 2000s. The defining structural feature of SS peptides is an alternating cationic/aromatic amino acid pattern. This combination causes them to:
- Cross the outer mitochondrial membrane without an active transporter, despite their charge
- Concentrate ~1,000-fold in the inner mitochondrial membrane through electrostatic attraction to the negatively charged cardiolipin head groups
- Bind cardiolipin selectively without disrupting other anionic phospholipids
Once parked at cardiolipin, elamipretide produces several measurable downstream effects:
- Stabilizes cristae architecture — the folded inner membrane structure that houses the electron transport chain
- Improves electron transport chain efficiency, which raises ATP synthesis
- Reduces production of reactive oxygen species (ROS) at complexes I and III, where leaky electron transfer is a primary ROS source
- Improves mitophagy (the cell's quality control system for damaged mitochondria) in models where it is impaired
Originally elamipretide was described as a free-radical scavenger, but the field has largely moved past that framing. The current consensus, supported by structural and biophysical data, is that its primary action is cardiolipin binding and cristae stabilization — and the antioxidant effect is a downstream consequence of healthier electron transport chains, not direct radical quenching.
TAZPOWER: The Trial That Got It Approved (Eventually)
The pivotal evidence package for FORZINITY centers on the TAZPOWER trial. The path from this study to approval is unusual and worth understanding.
Trial Design
TAZPOWER was a Phase II, randomized, double-blind, placebo-controlled, crossover study followed by a long-term open-label extension (OLE).
- N: 12 male patients with genetically confirmed Barth syndrome
- Randomized phase: 12 weeks, elamipretide 40 mg subcutaneous daily vs. placebo, then 4-week washout, then crossover
- Open-label extension: Up to 168 weeks of continuous elamipretide
Randomized Phase: Negative on Primary Endpoints
Here's the unusual part. In the randomized, placebo-controlled phase, elamipretide did not statistically beat placebo on the pre-specified primary endpoints (six-minute walk distance and total fatigue score).
In any standard regulatory framework, that's a failed trial. Most drugs do not survive a negative pivotal study.
Open-Label Extension: Sustained, Substantial Improvements
Where the picture changed is the long-term extension. Across 168 weeks of continuous treatment:
| Endpoint | Result at Week 168 |
|---|---|
| Six-minute walk distance | +96.1 m cumulative increase from baseline (P = .003) |
| Knee extensor muscle strength | Median +63 newtons from baseline (range 38–78) |
| Cardiac structure | Improvements in left ventricular stroke volume and end-systolic volume |
| Patient-reported function | Sustained improvements on Barth syndrome–specific assessments |
The argument Stealth and the FDA ultimately accepted: the 12-week randomized window was too short to detect a benefit in a slowly-remodeling muscle disease, but the long-term, within-patient improvements during the open-label extension — particularly in muscle strength — were both consistent and clinically meaningful in a population with no other treatment.
The FDA's integrated review acknowledges the unusual nature of this approval. Accelerated approval was granted based on muscle strength as a reasonably likely surrogate for clinical benefit, with confirmatory studies required.
This is, in other words, an approval that hinged on extreme rarity, mechanistic plausibility, and long-term observational improvement — not on a clean Phase III win. Reasonable people can disagree about whether the bar should have been higher; what's not in doubt is that families with Barth syndrome now have something where they previously had nothing.
The Other Trials: A Mixed but Informative Record
Outside Barth syndrome, elamipretide has been tested across several major indications. The pattern is instructive: clear biological signals, mixed effects on conventional endpoints, occasional surprises.
Heart Failure with Reduced Ejection Fraction (PROGRESS-HF)
Elamipretide was studied in HFrEF in the early 2020s. The Phase 2 PROGRESS-HF trial showed modest improvements in left ventricular end-systolic volume at higher doses, but did not produce the kind of dramatic effect that would justify a Phase 3 in HFrEF as a standalone strategy. That program is no longer active.
Heart Failure with Preserved Ejection Fraction (PROGRESS-HFpEF / EMBRACE-HFpEF)
This is where the cardiology story got more interesting. HFpEF is a notoriously difficult disease — the patient population is heterogeneous, and most therapies that work in HFrEF have failed here. But mitochondrial dysfunction in cardiac and skeletal muscle is a strong feature of HFpEF, which makes elamipretide mechanistically attractive.
In the HFpEF Phase 2 program, elamipretide was associated with improvements in peak oxygen consumption (peak VO₂) and patient-reported quality of life over short treatment periods. Stealth submitted an HFpEF NDA in late 2025, and the FDA granted Priority Review in January 2026 with a target action date in September 2026. That decision — pending as of this writing — would expand FORZINITY into a vastly larger indication if approved.
It's also a stress test. HFpEF is a common, well-defined population with rigorous endpoint expectations. Approval here would do more for the credibility of the mitochondrial peptide field than the Barth syndrome approval did.
Primary Mitochondrial Myopathy (MMPOWER-3)
In genetically confirmed primary mitochondrial myopathies (PMM), the Phase 3 MMPOWER-3 trial missed its primary endpoints of six-minute walk improvement and total fatigue. Some secondary measures showed small effects, but nothing that supported approval. The PMM program was discontinued.
The MMPOWER-3 result is a reminder that "mitochondrial dysfunction" is not a single disease. Different mitochondrial pathologies have different mechanisms, and a cardiolipin-targeting peptide is not universally helpful.
Dry AMD / Geographic Atrophy (ReCLAIM-2)
Mitochondrial dysfunction in retinal pigment epithelium is a leading hypothesis for the slow neurodegeneration of dry age-related macular degeneration. Stealth ran the ReCLAIM and ReCLAIM-2 trials evaluating elamipretide in dry AMD with geographic atrophy.
ReCLAIM-2 missed its formal primary endpoints (low-luminance visual acuity and geographic atrophy area), but showed something interesting on a secondary measure: slower degradation of the ellipsoid zone — the layer of the retina that holds photoreceptor mitochondria. Photoreceptors are among the most metabolically demanding cells in the body, and ellipsoid zone preservation is a biologically meaningful signal.
Stealth has since launched the Phase 3 ReNEW trial to confirm geographic atrophy benefit. As of mid-2026 the readout has not occurred. Dry AMD is one of the largest unmet-need populations in ophthalmology — a positive Phase 3 here would be a major event.
Aging Research: Where the Mitochondrial Peptide Story Started
The earliest excitement about SS-31 in the longevity community came from a series of preclinical papers showing that even a brief course of treatment could partially reverse age-related muscle dysfunction in old mice. A 2020 study in Aging Cell extended this to humans: a small trial in older adults with skeletal muscle mitochondrial dysfunction showed that an 8-day course of subcutaneous SS-31 measurably improved mitochondrial respiration and oxidative stress markers compared with baseline.
This is not, on its own, evidence that elamipretide is an anti-aging drug in any clinically actionable sense. It's evidence that the peptide's preclinical mechanisms reach human muscle and produce measurable effects on the cellular phenotype most directly tied to its mechanism.
It is also, importantly, why the longevity research community has been watching the FORZINITY approval more closely than the rare-disease community.
How Elamipretide Compares to Other Mitochondrial Peptides
Mitochondrial peptides as a class are still small and largely preclinical. Here's where elamipretide sits in the landscape:
| Peptide | Origin | Mechanism | Clinical Stage |
|---|---|---|---|
| Elamipretide (SS-31) | Synthetic SS-peptide | Cardiolipin binding, cristae stabilization | FDA-approved (Barth); HFpEF NDA pending; Phase 3 in dry AMD |
| MOTS-c | Mitochondrial-derived peptide (12-AA) | AMPK activation, metabolic reprogramming | Preclinical → early human (Japan) |
| Humanin / SHLP-2 / SHLP-6 | Mitochondrial-derived | Anti-apoptotic, metabolic, neuroprotective | Preclinical |
| MOTS-c analogs | Synthetic optimized | AMPK pathway with improved PK | Preclinical |
| Idebenone (small molecule, not a peptide) | Quinone analog | Electron transport bypass | Approved in Europe for LHON |
Two things stand out from this table.
First, elamipretide is in a category of one for clinical maturity. No other mitochondrial peptide has reached approval. Most are still in cell or animal studies.
Second, the others operate by different mechanisms — MOTS-c through AMPK signaling, humanin through anti-apoptotic and metabolic effects. Elamipretide's success doesn't validate those programs directly, but it does establish that the FDA will accept a mitochondrial-targeting peptide if the data support it. That regulatory precedent is meaningful.
What This Means for the Mitochondrial Peptide Field
A few implications worth being honest about.
1. A Rare-Disease Approval Is Not a Validation of "Mitochondrial Peptides for Aging"
It would be easy — and it is happening on social media — to translate "FDA-approved mitochondrial peptide" into "FDA-approved anti-aging therapy." That is not what the approval says. FORZINITY is approved for muscle strength in Barth syndrome on an accelerated pathway with confirmatory trials still required. It is not a sanctioned longevity intervention.
The long-term aging data on SS-31 is suggestive, mechanistically grounded, and worth continuing to study. It is not the same as a controlled trial in healthy older adults showing that elamipretide changes meaningful aging endpoints. That trial has not been done.
2. The HFpEF Decision in September 2026 Is the Real Test
If FORZINITY is approved for HFpEF, it stops being a niche rare-disease drug and becomes a tool with millions of potential patients. That would shift commercial dynamics, drive serious follow-on research investment, and make the next decade of mitochondrial peptide development meaningfully different from the last one.
If the HFpEF NDA fails, the broader mitochondrial peptide field loses momentum it has been building for years. The September 2026 PDUFA date is, in this sense, more important than the Barth approval was.
3. Off-Label Use Is Already Happening, and the Cost Profile Is Going to Be a Problem
FORZINITY's launch price for Barth syndrome will, like most ultra-rare disease drugs, be very high — likely six figures annually. Compounded SS-31 has been available through wellness clinics and the gray market for years at a tiny fraction of that cost. With FDA approval, three things are now in tension:
- Compounding rules tighten when an FDA-approved version exists in commercial supply
- Wellness-clinic demand for SS-31 is rising in tandem with the longevity narrative around the approval
- Quality and authenticity of compounded or research-grade SS-31 is highly variable
This is a familiar pattern from semaglutide and tirzepatide. Expect a similar regulatory and supply chain story to play out for elamipretide over the next 12–24 months.
4. The Approval Validates a Therapeutic Strategy, Not a Specific Compound
Cardiolipin as a drug target is now a clinically validated strategy. SS peptides are not the only way to address it. Other compounds in development — including small molecules and next-generation SS-peptide derivatives — now have a real precedent to build on.
This is how successful first-in-class approvals usually function. The approval often becomes more important for what it enables than for what it directly treats.
Safety and Side Effect Profile
The clinical safety record across more than a decade of trials and ~1,000 patients is, on balance, reassuring for a peptide drug.
Most common adverse events:
- Injection site reactions (the dominant issue — redness, induration, pain at the subcutaneous site)
- Headache
- Fatigue
- Nausea
- Upper respiratory tract infections
No notable signal for cardiac arrhythmia, hepatotoxicity, or hematologic adverse events across the major trial program.
Renal dosing: Reduce to 20 mg daily in severe renal impairment (eGFR < 30 mL/min, not on dialysis). The 40 mg dose has not been studied in dialysis patients.
Pregnancy / lactation: No human data; animal studies have not shown developmental toxicity at therapeutic doses, but as with most newly approved drugs, use during pregnancy should be a clinician decision.
For the longevity-oriented self-experimentation community using compounded SS-31, the FDA-approved label now provides what was previously missing — a reference dosing schedule (40 mg subcutaneous daily) and a documented adverse event profile from controlled trials. That doesn't make off-label use safe; it makes the unknowns somewhat smaller.
What to Watch Next
The next 12 months are likely to be the most consequential in elamipretide's history.
- September 2026: HFpEF PDUFA target action date. A positive decision opens elamipretide into a multi-million-patient population.
- 2026–2027: Dry AMD Phase 3 (ReNEW) readout. If geographic atrophy progression slows on a primary endpoint, ophthalmology becomes a major indication.
- Ongoing: Confirmatory studies for the Barth syndrome accelerated approval. Failure here could in principle reverse the approval, though that's rare.
- Emerging: Investigator-initiated and academic studies on aging, sarcopenia, and post-COVID mitochondrial dysfunction are accumulating. None will likely reach approval anytime soon, but they will shape clinical impressions and demand.
For the broader peptide research community, the question is whether elamipretide ends up looking like the first of many FDA-approved mitochondrial peptides — or like a one-off enabled by ultra-rare disease pathways. The HFpEF and AMD readouts will largely determine which.
The Bottom Line
After more than a decade in clinical development, multiple mid-stage failures, and a strange path through a 12-patient pivotal trial, elamipretide has become the first FDA-approved mitochondria-targeted peptide drug. The label is narrow. The mechanism is broad.
The Barth syndrome approval was the door opening. What walks through it next — HFpEF, geographic atrophy, eventually maybe sarcopenia or aging research — is what will determine whether mitochondrial peptides become a real therapeutic class or remain a small niche.
For now, two things are true at once:
- Elamipretide is a real drug with a real FDA approval and a real mechanism. The mitochondrial peptide concept is no longer purely theoretical.
- Elamipretide is not an FDA-approved aging therapy, and presenting it that way overstates what the data shows.
Both can be true. The interesting questions are no longer about whether the peptide does anything — that's been answered — but about how much it does, in whom, and over what time scale. Those are the answers the next two to three years of trials should produce.
This article is for educational and research purposes only. It is not medical advice. FORZINITY (elamipretide HCl) is FDA-approved exclusively for the improvement of muscle strength in Barth syndrome patients weighing at least 30 kg. Any other use, including for heart failure, age-related macular degeneration, or general aging concerns, is investigational. Always consult a qualified healthcare provider before considering any peptide therapeutic.